

## QVQ Targets

mrt-19



Cancer			Infectious diseases			Age related diseases								
						Tissue Repair			Neuromuscular			Cardiovascular		
Target	CD #	Phase	Target	CD #	Phase	Target	CD #	Phase	Target	CD #	Phase	Target	CD #	Phase
Her 2	CD340	5 *	Clostridium difficile toxin B		5	BMP2/4		5	Vimentin		5	Vimentin		5
BMP2/4		5	HIV neutr. CD4bs (J3)		5	BMP7		5	PABPN1		5	CD14	CD14	4
CA IX		5	HIV various bi-heads		5	Hydroxyapatite (HA)		5	CXCR4	CD184	4	C3		3
CEA		5	Rotavirus		5	CXCR4	CD184	4	DUX4		4	Catalase		3
EGFR		5	Vimentin		5	DKK		4	Integrin β1	CD29	4	Clusterin		3
Vimentin		5	Candida albicans ECE1		4	DNABII		4	NCAM	CD56	4	Factor VIII		3
B7H3	CD276	4	Clostridium difficile toxin A		4	Integrin β1	CD29	4	Tf Receptor	CD71	4	FcyRIII	CD16	3
cMet		4	CXCR4	CD184	4	VEGF		4	Amyloid β		3	Troponin C		3
CXCR4	CD184	4	DCSign		4	B7-1	CD80	3	BACE		3			
EpCAM	CD326	4	DNABII		4	BMP6		3	FcyRIII	CD16	3			
PD-L1	CD274	4	HIV neutr. Bridging sheet		4	Collagen		3	IL1-R	CD121	3			
PD-L2	CD273	4	HIV neutr. gp41		4	Fibronectin [FN]		3						
PSA		4	HIV neutr. gp41/gp140		4	IL1-R	CD121	3						
Tf Receptor	CD71	4	HIV neutr. V3 loop		4	MST1R	CD136	3						
uPAR		4	P24 (HIV)		4	RM3/1 antigen	CD163	3						
VEGF		4	Candida alb. Germtubes		3	Vitronectin		3						
CAVII		3	Candida alb. Hyphae		3									
Hyaluronic acid receptor	CD44	3	Norovirus		3									
PKC ε		3	Pseudomonas Flagellum		3									
PKC θ		3												
T cell receptor	CD3	3												

### Phases explained

<b>5*</b>	VHH characterized <i>in vivo</i> . Produced under GMP conditions.
<b>5</b>	VHH characterized <i>in vivo</i> . <b>Purified VHH (C-Direct)</b> available from yeast production. Ready for GMP production.
<b>4</b>	VHH has been characterized <i>in vitro</i> . Purified VHH available from E.coli production.
<b>3</b>	<b>Lead molecules</b> with high affinity have been identified. Ready for characterization <i>in vitro</i> .
<b>2</b>	<b>Selections</b> for monoclonal VHH were performed. Ready for further characterization.
<b>1</b>	<b>Immunizations</b> of llamas were performed. Ready for monoclonal VHH selection.

Targets under investigation														
CTLA-4	CD152	2	Flippase		2	Sclerostin SOST		2	CD14	CD14	2	ApoE		2
BMP-R1		2	NEF (HIV)		2	Aggrecan		1	CRYM1		2	GC globulin		2
Eps15		2	OMP E.Coli		2	Folate Receptor		1	Dysferlin		2	LDL		2
Her3		2	OMP T		2	IL1β		1	Emerin		2	Leptin		2
HIF1α		2	S. aureus		2	Matrillin		1	FRG1		2	OxLDL		2
Hyaluronic acid receptor v6	CD44v6	2	S. epidermidis		2	MMP13		1	HMGB1		2	SOD		2
VLA-3 intergrin	CD49c	2	CCR5	CD195	1				Huntingtin		2	Troponin T		2
p53		1	E. faecium		1				MPO		2	GABARAPL1		1
OX40L	CD252	1							Myostatin		2			
4-1BB Ligand	CD137L	1							PITX1		2			
CCR5	CD195	1							Tropomyosin		2			
SLC amino acid transporters		1							Actin		1			
									IL1β		1			
									p53		1			